Iconovo AB (publ) (STO:ICO)
Sweden · Delayed Price · Currency is SEK 1.405
+0.080 (6.04%)
Sep 4, 2026, 5:22 PM CET
Iconovo AB Earnings Call Transcripts
Fiscal Year 2026
-
Revised summary: The company is shifting from a tech platform to monetizing a diverse pipeline of inhaled medicines, including generics and biologics. Regulatory changes and a patent cliff offer market opportunities. Key projects are in licensing and preclinical stages, with partnerships and funding supporting full pharma operations and long-term value.